New Wave Holdings Corp Appoints Dr. Wade Davis to Psychedelic Research Advisory Board
New Wave Holdings Corp. (CSE: SPOR, OTC: TRMNF) has appointed Dr. Wade Davis to its Psychedelic Research Advisory Board. This strategic move aims to enhance the company's focus on developing psychedelic-derived treatments for neuropsychiatric diseases, including anxiety and PTSD. Dr. Davis, a distinguished anthropologist and ethnobotanist, will assist in shaping research and intellectual property strategies. New Wave Holdings is leveraging its investment in Anahit Therapeutics to advance active psychedelic compounds and medicinal mushroom health products.
- Appointment of Dr. Wade Davis brings significant expertise to the Psychedelic Research Advisory Board.
- Focus on developing psychedelic-based treatments for neuropsychiatric diseases may lead to innovative product offerings.
- Investment in Anahit Therapeutics supports the development of active psychedelic compounds.
- Potential risks related to competition in the psychedelic sector could impact growth.
- Dependence on successful research outcomes to validate product development strategies.
TORONTO, Aug. 31, 2020 /PRNewswire/ - NEW WAVE HOLDINGS CORP. (the "Company" or "New Wave Holdings") (CSE: SPOR), is an investment issuer focused on the burgeoning psychedelic and esports sectors. In the psychedelic sector New Wave Holdings focuses on active psychedelic compounds, functioning mushroom product lines, and develop an IP portfolio focusing on psilocybin, LSD, MDMA, and ketamine derived treatments for neuropsychiatric diseases, announces that it has brough on Dr. Wade Davis, Ph. D. to it's Psychedelic Research Advisory Board ("Advisory Board").
Psychedelic Sector
New Wave Holdings, through it's investment in Anahit Therapeutics Ltd. ("Anahit"), will focus on active psychedelic compounds, functioning mushroom product lines derived from lions mane, reishi, and cordyceps mushrooms, and developing an IP portfolio focused on psilocybin, LSD, MDMA, and ketamine derived treatments for neuropsychiatric diseases (Addiction, Depression, Anxiety, & PTSD). The Company is developing a series of medicinal mushroom health products for the pharmaceutical and nutraceutical industries.
The Company is pleased to announce that Dr. Wade Davis has agreed to play an integral role on the Psychedelic Research Advisory Board. His role will to advise on research that supports the Company's goal of development and commercialization of psychedelic compound derived neuropsychiatric treatments, assisting in the development an IP strategy, acting as a liaison to key industry players and providing such introductions, and supporting the Company in new developments and providing feedback and insight. The Advisory Board will evaluate the potential positive effects its medicinal mushroom formulations could have on individuals suffering from indications such as anxiety/depression and Post Traumatic Stress Disorder (PTSD), bereavement and emotional disturbances as well as stress and substance abuse disorders.
Dr. Wade Davis, Ph.D.
Wade Davis is a writer, photographer, and filmmaker whose work has taken him from the Amazon to Tibet, Africa to Australia, Polynesia to the Arctic. Explorer-in-Residence at the National Geographic Society from 2000 to 2013, he is currently Professor of Anthropology and the BC Leadership Chair in Cultures and Ecosystems at Risk at the University of British Columbia. Author of 23 books, including One River, The Wayfinders and Into the Silence, winner of the 2012 Samuel Johnson prize, the top nonfiction prize in the English language, he holds degrees in anthropology and biology and received his Ph.D. in ethnobotany, all from Harvard University. His many film credits include Light at the Edge of the World, an eight-hour documentary series written and produced for the NGS. Davis, one of 20 Honorary Members of the Explorers Club, is the recipient of 12 honorary degrees, as well as the 2009 Gold Medal from the Royal Canadian Geographical Society, the 2011 Explorers Medal, the 2012 David Fairchild Medal for botanical exploration, the 2015 Centennial Medal of Harvard University, the 2017 Roy Chapman Andrews Society's Distinguished Explorer Award, the 2017 Sir Christopher Ondaatje Medal for Exploration, and the 2018 Mungo Park Medal from the Royal Scottish Geographical Society. In 2016, he was made a Member of the Order of Canada. In 2018 he became an Honorary Citizen of Colombia. His latest book, Magdalena: River of Dreams, will be published by Knopf in September 2020.
Explorer-in-Residence at the National Geographic Society from 2000 to 2013, Wade Davis is currently Professor of Anthropology at the University of British Columbia. Author of 23 books, including One River, The Wayfinders and Into the Silence, he holds degrees in anthropology and biology and received his Ph.D. in ethnobotany, all from Harvard University. In 2016, he was made a Member of the Order of Canada. In 2018 he became an Honorary Citizen of Colombia. His latest book, Magdalena: River of Dreams, will be published by Knopf in September.
ABOUT NEW WAVE HOLDINGS CORP.
New Wave Holdings Corp. (CSE: SPOR, FWB: 0XM2, OTC:TRMNF) is an investment issuer focused on the burgeoning psychedelic and esports sectors. In the psychedelic sector New Wave will focus on active psychedelic compounds, functioning mushroom product lines, and develop an IP portfolio focusing on psilocybin, LSD, MDMA, and ketamine derived treatments for neuropsychiatric diseases.
Investors interested in connecting with New Wave Holdings can learn more about the company and contact the team at http://newwavecorp.com.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
The securities issued in connection with the Transaction and the Offering have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "1933 Act"), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.
FORWARD-LOOKING INFORMATION DISCLAIMER
Certain statements contained in this news release may constitute forward-looking information, including but not limited to, expansion of operations. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information. The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of competitive factors and competition for investment opportunities, challenges relating to operations in international markets, transaction execution risk, changes to the Company's strategic growth plans, and other factors, many of which are beyond the control of the Company. The Company believes that the expectations reflected in the forward-looking information are reasonable based on current expectations and potential investment pipeline, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof, and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.
View original content to download multimedia:http://www.prnewswire.com/news-releases/new-wave-holdings-corp-appoints-dr-wade-davis-to-psychedelic-research-advisory-board-301120807.html
SOURCE New Wave Holdings Corp.
FAQ
What is the significance of Dr. Wade Davis's appointment at New Wave Holdings?
What are New Wave Holdings' main focus areas?
How might Dr. Davis's expertise impact New Wave Holdings?
What is the role of Anahit Therapeutics in New Wave Holdings' strategy?
What are the potential challenges facing New Wave Holdings in the psychedelic sector?
